NCT05316857View on ClinicalTrials.gov

DDI Study of Orelabrutinib

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

December 16, 2021

Primary Completion Date

January 4, 2022

Study Completion Date

June 13, 2022

Conditions
Healthy Person
Interventions
DRUG

Orelabrutinib + Rifampin

Orelabrutinib + Rifampin

DRUG

Orelabrutinib + Itraconazole

Orelabrutinib + Itraconazole

Trial Locations (1)

215000

The First Affiliated Hospital of Soochow University, Suzhou

All Listed Sponsors
lead

Beijing InnoCare Pharma Tech Co., Ltd.

INDUSTRY

NCT05316857 - DDI Study of Orelabrutinib | Biotech Hunter | Biotech Hunter